445
Views
3
CrossRef citations to date
0
Altmetric
Editorial

The ODAC chronicles: Part 1. My first ODAC experience

Pages 709-712 | Published online: 10 Jan 2014

REFERENCES

  • Grillo-Lopez AJ. Cancer therapies crisis in the USA. Expert Rev Anticancer Ther. 3(5), 579–582 (2003).
  • Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. Clin. Oncol 21,1404–1411 (2003).
  • Code of Federal Regulations. Establishment of Standing Technical Advisory Committees for Human Prescription Drugs, Title 21, Volume 1, Part 14, Subpart I, Section 14.160 (2003).
  • Grillo-Lopez AJ. Rituximab: an insider'shistorical perspective. Semin. Oncol 27(6 Suppl. 12), 9–16 (2000).
  • Grillo-Lopez AJ. Rituximab: the first decade (1993–2003). Expert Rev. Anticancer Ther. 3(6), 767–779 (2003).
  • Grillo-Lopez AJ. Rituximab: clinical development of the first therapeutic antibody for cancer. In: Applications of Pharmaceutical Biotechnology a Comprehensive Textbook. Kayser O, Muller R (Eds), Wiley-VCH Verlag, Weinheim, Germany, 205–221 (2003).

Website

  • Advisory committee industry representatives www.fda.gov/oc/advisory/industry.htlm (Accessed September 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.